Showing 81 - 100 results of 16,595 for search '(( 50 ((((ng decrease) OR (nn decrease))) OR (a decrease)) ) OR ( 50 we decrease ))', query time: 0.43s Refine Results
  1. 81

    Supramolecular DNA Photonic Hydrogels for On-Demand Control of Coloration with High Spatial and Temporal Resolution by Yixiao Dong (2174902)

    Published 2021
    “…We solve this problem by creating a DNA hydrogel system that shows a 50 000-fold decrease in modulus upon heating by ∼10 °C. …”
  2. 82

    Supramolecular DNA Photonic Hydrogels for On-Demand Control of Coloration with High Spatial and Temporal Resolution by Yixiao Dong (2174902)

    Published 2021
    “…We solve this problem by creating a DNA hydrogel system that shows a 50 000-fold decrease in modulus upon heating by ∼10 °C. …”
  3. 83

    Supramolecular DNA Photonic Hydrogels for On-Demand Control of Coloration with High Spatial and Temporal Resolution by Yixiao Dong (2174902)

    Published 2021
    “…We solve this problem by creating a DNA hydrogel system that shows a 50 000-fold decrease in modulus upon heating by ∼10 °C. …”
  4. 84

    Supramolecular DNA Photonic Hydrogels for On-Demand Control of Coloration with High Spatial and Temporal Resolution by Yixiao Dong (2174902)

    Published 2021
    “…We solve this problem by creating a DNA hydrogel system that shows a 50 000-fold decrease in modulus upon heating by ∼10 °C. …”
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  10. 90

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100